KECORT Study: An International e-Delphi Study on the Treatment of KEloids Using Intralesional CORTicosteroids in...

Area of Science:

• Dermatology
• Plastic Surgery
• Wound Healing

Background:

• Intralesional corticosteroid administration (ICA) is a primary treatment for keloids.
• Significant variability exists in current ICA clinical practices, hindering treatment result comparisons.

Purpose of the Study:

• To achieve international expert consensus on intralesional corticosteroid administration (ICA) for keloid treatment.
• To develop evidence-based clinical recommendations for physicians managing keloids.

Main Methods:

• An international panel of 23 dermatologists and plastic surgeons specialized in keloid treatment participated.
• A two-round online e-Delphi survey was conducted, followed by consensus meetings.
• Consensus was defined as agreement by at least 75% of participants.

Main Results:

• Consensus was achieved on treatment goals, indications, preferred corticosteroid (triamcinolone acetonide 40 mg/mL), maximum dosage (80 mg/month), injection intervals (4 weeks), pain minimization, syringe/needle size (1 mL, 25/27G), endpoint (blanching), and technique (avoiding subcutaneous injection, multiple passes for firm keloids).
• Areas without consensus included specific dosing, local anesthesia methods, and injection sites.

Conclusions:

• This e-Delphi study provides crucial clinical recommendations for ICA in keloid management.
• Implementing these consensus-based guidelines can enhance treatment uniformity and potentially improve keloid treatment outcomes.